文献速递神经与头颈病理细胞病理与分子病理

临床侵袭性滤泡细胞来源甲状腺癌:组织分子特征及新基因融合发现

Clinically aggressive follicular cell-derived thyroid carcinoma: A comprehensive series with histomolecular characterization and discovery of novel gene fusions.
PubMed 文献 · Hum Pathol · 2024-10-28

该研究纳入57例侵袭性转移和/或放射性碘难治性甲状腺癌患者(排除未分化癌),进行组织病理学分析和下一代测序及RNA测序。乳头状癌和高grade甲状腺癌占主导,常见BRAF V600E、TERT启动子和RAS突变;

要点

  • 侵袭性甲状腺癌中BRAF V600E、TERT启动子和RAS突变常见
  • 发现UGGT1::TERT、BTBD9::TERT和TG::IGF1R三个新融合

核心结论

  • TERT异常在侵袭性表型中具有重要意义,新融合可能驱动侵袭行为并为靶向治疗提供线索。

研究设计与样本

  • 研究纳入57例侵袭性转移和/或放射性碘难治性甲状腺癌患者,排除未分化癌,进行组织病理学分析、下一代测序和RNA测序。

主要发现

  • 组织病理学显示乳头状癌和高grade甲状腺癌占主导。
  • 分子分析发现BRAF V600E、TERT启动子和RAS突变常见。
  • 发现三个新融合:UGGT1::TERT、BTBD9::TERT和TG::IGF1R。
  • UGGT1::TERT与放射性碘难治性高细胞型PTC相关,BTBD9::TERT与高grade滤泡型PTC相关,TG::IGF1R与嗜酸细胞癌相关。

临床怎么用

  • 对侵袭性转移或放射性碘难治性甲状腺癌可考虑分子检测以识别TERT异常及可靶向融合。

局限性

  • 新融合的诊断和预后意义需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thyroid cancer rates are increasing, mostly with a good prognosis and less than 2 % of cases are more aggressive. Recent efforts focus on understanding molecular events predicting tumor aggressiveness and treatment targets in advanced thyroid cancer. This study concerned 57 patients with aggressive metastatic, and/or radioiodine-refractory thyroid carcinomas, excluding anaplastic cases. Molecular profiling, including next-generation sequencing and RNA sequencing, was conducted to dissect the complex molecular landscape of these aggressive tumors. Histopathological analysis indicated that papillary carcinomas and high-grade thyroid carcinomas were predominant. The molecular analysis revealed a spectrum of mutations, with prevalent occurrences of BRAF V600E, TERT promoter, and RAS mutations. RNA sequencing identified ten gene fusions, such as NTRK and RET fusions. Three novel fusions were discovered: UGGT1::TERT, BTBD9::TERT, and TG::IGF1R, potentially driving aggressive behavior. UGGT1::TERT was linked to radioiodine-refractory tall cell PTC, BTBD9::TERT to high-grade follicular PTC, and TG::IGF1R to oncocytic carcinoma. These findings underscore the importance of TERT alterations in aggressive phenotypes and offer insights into molecular mechanisms guiding targeted therapies. Further research is necessary to confirm their significance as diagnostic and prognostic markers in thyroid cancer.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Alsugair Z, Descotes F, Lopez J, et al. Clinically aggressive follicular cell-derived thyroid carcinoma: A comprehensive series with histomolecular characterization and discovery of novel gene fusions. Hum Pathol. 2024. PMID: 39490534. doi:10.1016/j.humpath.2024.105674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。